已收盘 11-20 16:00:00 美东时间
+0.710
+1.84%
Source: TradePulse / Data as of 2:00PM EST Market Overview Recent aggregate flow data reflects continued participation across several key market segments, particularly financial services, technology,
11-19 04:39
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the "Notes"). Teva
09-10 18:10
Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.
07-08 02:21
Teva to acquire Emalex for $700 million, posts Q1 earnings beat, and maintains 2026 outlook amid margin and buyback plans.
04-30 01:52
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
04-16 23:37
Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.
04-02 01:36
Teva Pharmaceutical Industries Ltd's (NYSE:TEVA) short interest as a percent of...
03-02 21:00
FDA accepts Teva's application for the monthly schizophrenia injection TEV-749 as shares show mixed momentum signals.
02-23 21:48
Corcept Therapeutics shares plunged Thursday morning after a federal appeals court upheld a ruling that Teva Pharmaceuticals' proposed generic does not infringe two Korlym-related patents.
02-20 00:48
Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.
01-13 01:26